Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Grande Portage Resources (V.GPG) Initiates Sensor-Based Ore Sorting Testwork (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Curative Biotechnology Inc CUBT

Healthcare Biotechnology
Curative Biotechnology, Inc. is a development stage biomedical company focused on therapies for rare diseases. The Company is identifying, acquiring, and developing disease modifying therapeutic drug candidates with a concentration on rare disease indications. It has ongoing programs in three different therapeutic areas: degenerative eye disease, infectious disease, and neuro-oncology. It is... see more

Recent & Breaking News (OTCPK:CUBT)

Curative Biotechnology, Inc. Announces Addition of Dr. Nicholas Boulis to Scientific and Clinical Advisory Board

GlobeNewswire September 2, 2021

Curative Biotechnology, Inc. Files 2021 First Quarter Financials and Issues Letter to Shareholders

GlobeNewswire May 25, 2021

Connectyx Reports Fiscal Year 2020 Financial Results

GlobeNewswire March 9, 2021

Connectyx Announces Key Biotech Industry Veterans to Management Team

PR Newswire February 11, 2021

Connectyx Announces Grant of Exclusive Worldwide License from National Institutes of Health for Repurposing Metformin to Treat Degenerative Eye Disease

PR Newswire February 4, 2021

Connectyx Announces Name Change to Curative Biotechnology and Secures Bridge Financing

GlobeNewswire November 23, 2020

Connectyx Announces Grant of License from National Institutes of Health for Use of Novel Monoclonal Antibody to Treat Glioblastoma

GlobeNewswire October 16, 2020

Connectyx Technologies Holdings Group, Inc. Announces Definitive Agreement with Mid-Atlantic BioTherapeutics, Inc. for Treatment of Symptomatic Rabies

GlobeNewswire October 9, 2020

Connectyx Technologies Holdings Group, Inc. Announces Strategic Relationship with Mid-Atlantic BioTherapeutics, Inc. for Treatment of Symptomatic Rabies

GlobeNewswire August 27, 2020

Connectyx in Licensing Discussions for Novel Monoclonal Antibody to Treat Pediatric Glioblastoma

GlobeNewswire July 6, 2020

Connectyx Welcomes I. Richard Garr, Esq. to Company's Scientific Advisory Board

GlobeNewswire May 19, 2020

Connectyx Welcomes Dr. Michael Grace and Dr. Ronald Bordens to the Company's Scientific Advisory Board

GlobeNewswire May 8, 2020

Connectyx Technologies Issues Shareholder Update

GlobeNewswire May 1, 2020

Connectyx Technologies Holdings Group Returns to OTC Current Status

GlobeNewswire April 13, 2020

Connectyx Technologies Holdings Group announces Shareholder Update

GlobeNewswire March 6, 2020

Connectyx Receives a 7 Million USD Funding Commitment From a Chinese Institution for Personal Early Response System Software (PERS)

Business Wire February 6, 2020